The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2015

Filed:

Nov. 26, 2014
Applicants:

Chandrashekar Giliyar, North Maple Grove, MN (US);

Satish Kumar Nachaegari, Salt Lake City, UT (US);

Chidambaram Machiappan, Salt Lake City, UT (US);

Mahesh V. Patel, Salt Lake City, UT (US);

Srinivasan Venkateshwaran, Salt Lake City, UT (US);

Inventors:

Chandrashekar Giliyar, North Maple Grove, MN (US);

Satish Kumar Nachaegari, Salt Lake City, UT (US);

Chidambaram Machiappan, Salt Lake City, UT (US);

Mahesh V. Patel, Salt Lake City, UT (US);

Srinivasan Venkateshwaran, Salt Lake City, UT (US);

Assignee:

Spriaso LLC, Salt Lake City, UT (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/485 (2006.01); A61K 31/194 (2006.01); A61K 31/4402 (2006.01); A61K 45/06 (2006.01); A61K 31/09 (2006.01); A61K 31/137 (2006.01); A61K 9/20 (2006.01);
U.S. Cl.
CPC ...
A61K 31/485 (2013.01); A61K 9/2054 (2013.01); A61K 31/09 (2013.01); A61K 31/137 (2013.01); A61K 31/194 (2013.01); A61K 31/4402 (2013.01); A61K 45/06 (2013.01);
Abstract

A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm˜ for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm˜ provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.


Find Patent Forward Citations

Loading…